Week in Review: June 3 - Insights
Today's highlights include: Spread of monkeypox underscores need for physicians to be ready to understand, Pfizer completes application to FDA for vaccine for children under 5, and connect is key to supporting multiple sclerosis patients.
Mayo Clinic's Accurate Amyloidosis Typing Test Leads to Effective Treatment - Insights
When the type of amyloidosis is appropriately determined by accurate and effective laboratory testing, it can be treated properly.
Pathology consultation - Insights
Learn more about how Mayo Clinic Laboratories consultative pathology practice, which is supported by more than 100 board-certified pathologists, can provide expertise on any case.
Autoimmune neurology evolution - Insights
Patients with autoimmune neurologic conditions deserve the best chance at an accurate diagnosis. These answers can make a real difference in a patient’s treatment and quality of life.
Malabsorption disorders - Insights
Malabsorption syndrome encompasses several disorders that impact the ability of the small intestine to absorb macronutrients, micronutrients, or both. Because malabsorption syndrome can be caused by myriad factors, identifying the...
Helicobacter pylori, or H. pylori, is one of the world’s most common chronic bacterial infections. Estimated to impact 4.4 billion individuals globally, H. pylori affects 35% to 89% of children, depending the on the geographic region in...
Test panel guides diagnosis of early onset IBD: Ann Moyer, M.D., Ph.D. - Insights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' test panel provides comprehensive evaluation of patients with suspected monogenic early onset inflammatory bowel disease, or IBD. Accurate diagnosis is key to guiding therapy...
Assay stratifies pregnant women's preeclampsia risk: Joshua Bornhorst, Ph.D. - Insights
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal...
Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D. - Insights
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and...
Learn why liquid biopsy testing is a viable alternative to tissue-based biopsy testing for certain patients with cancer.